Thus, clarifying the critical role of C-MYC in the effect of CpG 685 on B-ALL cells and its regulatory mechanism is the key to optimizing CpG 685-based precision therapy against B-ALL. This evidence concerns the gene MYC and acute lymphoblastic leukemia.